OutsideIn Research - Special Report on InVivo Therapeutics ($NVIV)
InVivo
Therapeutics
Holdings,
Inc. (OTCBB: NV
IV) is
developing
novel
technologies
for
the
treatment
of
spinal
cord
injuries
(SCI).
There
are
12,000
SCIs
in
the
U.S.
annually
and
approximately
350,000
chronic
patients.
With no successful treatment currently available, existing approaches cost over $5 billion annually.
The first product will be a biocompatible/biodegradable polymeric scaffold device for surgical implantation adjacent to the acute SCI lesion in the critical hours following injury. In extensive trials in non-human primates, treated animals showed a reversal of paralysis and a return of normal motor function within days of treatment. An IDE has been filed and human trials should begin by early in 1Q 2012.
Other SCI products in the company’s development pipeline:
- An Injectable Biocompatible Hydrogel for controlled release of methylprednisolone.
- Use of Autologous Neural Stem Cells to seed a patient’s stem cells into a biodegradable polymeric scaffold to regenerate tissue in chronic cases where the spinal cord has already been damaged.
The biopolymer scaffold combines the blockbuster potential of a new therapeutic drug (at projected 90% gross profit margins) with the development timeline and risk profile of a medical device. Our research subsidiary, Outside-In Research, LLC has issued a research report dated 8/8/11 in which revenues from the first product (scaffold device) were estimated to exceed $150 million in the next 3-4 years and purchase of NVIV stock was strongly recommended.
In addition to its own products, InVivo has exclusive worldwide rights to the development and sale of:
…any biomaterial device used as an extracellular matrix either by itself or in combination with drugs, growth factors and human stem cells for treating spinal cord injury, or for parts of the peripheral nervous system, the cavernous nerve surrounding the prostate, the brain, retina or cranial nerve.
This is strategically prime IP territory for any medical device company, especially for a young enterprise with a market cap of less than $60 million. It suggests that InVivo has a wide range of licensing and collaborative possibilities with other companies in the burgeoning field of neurological therapies and devices.
www.OutsideInResearch.com.
-Dave Talbot
ProActive Capital Indexes
See ProActive's Disclaimer